The FDA’s new leadership must give rare disease patients a clearer path

At her confirmation hearing, Dr. Heidi Overton, President Donald Trump’s nominee to lead the Food and Drug Administration, called rare-disease treatments a “key priority.” The agency is also shaping PDUFA VIII, a five-year agreement that will determine FDA funding and its approach to reviewing new drugs. This is a rare opportunity and a serious responsibility. […]

Read it at Washington Examiner ↗

← Front page